ReviewChinese clinical oncology2017
Inherited pancreatic cancer.
Review in Chinese clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Polymorphisms within autophagy-related genes as susceptibility biomarkers for pancreatic cancer: A meta-analysis of three large European cohorts and functional characterization.International journal of cancer · 2025Pooled it
- Molecular Targets for the Diagnosis and Treatment of Pancreatic Cancer.International journal of molecular sciences · 2024Review
- Pancreatic ductal adenocarcinoma: exploring clinicopathological trends and racial disparities in a comprehensive U.S. population-based study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Article
- Review
- Biomarkers for Early Cancer Detection: A Landscape View of Recent Advancements, Spotlighting Pancreatic and Liver Cancers.ACS pharmacology & translational science · 2024Review
- The concomitant use of the renin-angiotensin system inhibitors and survival outcomes of patients with pancreatic adenocarcinoma: an analysis from a tertiary center.Therapeutic advances in medical oncology · 2024Article
- Endoscopic innovations in diagnosis and management of pancreatic cancer: a narrative review and future directions.Therapeutic advances in gastroenterology · 2024Review
- Clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.Cancer chemotherapy and pharmacology · 2023Article
- Identification of key biomarkers and associated pathways of pancreatic cancer using integrated transcriptomic and gene network analysis.Saudi journal of biological sciences · 2023Article
- The anti-cancer effect and mechanism of animal scale-derived extract on malignant melanoma cells.Scientific reports · 2023Article
- A deep learning algorithm to predict risk of pancreatic cancer from disease trajectories.Nature medicine · 2023Article
- An Insight into miR-1290: An Oncogenic miRNA with Diagnostic Potential.International journal of molecular sciences · 2022Review
- Article
- Examination of ATM, BRCA1, and BRCA2 promoter methylation in patients with pancreatic cancer.Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] · 2021Article
- PRSS1 Upregulation Predicts Platinum Resistance in Ovarian Cancer Patients.Frontiers in cell and developmental biology · 2020Article
- Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2019Article
- Prevalence of Germline Mutations Associated With Cancer Risk in Patients With Intraductal Papillary Mucinous Neoplasms.Gastroenterology · 2019Article
- Pancreatic cancer in young adults: changes, challenges, and solutions.OncoTargets and therapy · 2019Review
- Pancreatic cancer: A review of clinical diagnosis, epidemiology, treatment and outcomes.World journal of gastroenterology · 2018Review
- Pancreatic Cancer: A Review of Risk Factors, Diagnosis, and Treatment.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Pancreatic cancers arise through a series of genetic events both inherited and acquired. Inherited genetic changes, both high penetrance and low penetrance, are an important component of pancreatic cancer risk, and may be used to characterize populations who will benefit from early detection. Furthermore, pancreatic cancer patients with inherited mutations may be particularly sensitive to certain targeted agents, providing an opportunity to personalized treatment. Family history of pancreatic cancer is one of the strongest risk factors for the disease, and is associated with an increased risk of caners at other sites, including but not limited to breast, ovarian and colorectal cancer. The goal of this chapter is to discuss the importance of family history of pancreatic cancer, and the known genes that account for a portion of the familial clustering of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.